Durvalumab: an investigational agent for unresectable hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Investigational Drugs"
DOI: 10.1080/13543784.2022.2033208
Abstract: ABSTRACT Introduction Programmed death 1 (PD1), programmed death ligand 1 (PD-L1), and cytotoxic T lymphocyte associated protein 4 (CTLA-4) are proteins involved in the modulation of immune response, which are upregulated in hepatocellular carcinoma (HCC)… read more here.
Keywords: hepatocellular carcinoma; agent unresectable; investigational agent; durvalumab investigational ... See more keywords